Treatment for Interstitial Cystitis/Bladder Pain Syndrome

Introduction to Treatment Guidelines

• The American Urological Association recommends beginning with behavioral modifications and self-care practices for all patients, then escalating systematically through oral medications, intravesical therapies, and finally advanced interventions only for refractory cases 1, 2

First-Line: Behavioral Modifications and Self-Care

• Patients should start with conservative measures, including dietary management, before pharmacologic intervention 1, 2
• The Interstitial Cystitis Association suggests eliminating known bladder irritants, such as coffee, citrus products, and spicy foods, to help manage symptoms 1
• Implementing an elimination diet can help identify personal trigger foods 1
• Altering urine concentration through strategic fluid management can help dilute urinary irritants 1, 2
• Applying local heat or cold over the bladder or perineum can provide symptomatic pain relief 1, 2
• Practicing stress management techniques, such as meditation and imagery, can help reduce symptoms 1, 2
• Performing pelvic floor muscle relaxation exercises, rather than strengthening exercises, can help alleviate symptoms 1, 2

Second-Line: Oral Medications

• The American College of Physicians recommends advancing to pharmacologic therapy, including amitriptyline, when behavioral modifications prove insufficient 3, 4, 5
• Amitriptyline should be started at 10 mg daily and titrated up to 100 mg per day as tolerated, with Grade B evidence for symptom improvement superior to placebo 1, 2
• Pentosan polysulfate sodium is the only FDA-approved oral medication for IC/BPS, with a dose of 100 mg three times daily, and requires mandatory ophthalmologic monitoring due to risk of macular damage and ocular toxicity 1, 2

Second-Line: Intravesical Therapies

• Intravesical treatments, including heparin and lidocaine, can be used concurrently with or following oral medications 3, 4, 5
• Heparin can repair the damaged glycosaminoglycan layer of the bladder and provide clinically significant symptom improvement 1, 2
• Lidocaine provides rapid onset temporary relief of bladder pain 1, 2

Third-Line: Cystoscopy with Hydrodistension

• Cystoscopy should be performed when second-line treatments fail, to determine anatomic bladder capacity and identify fibrosis-related capacity reduction 2
• High-pressure and long-duration hydrodistension should be avoided to minimize risk of bladder rupture and sepsis 2

Fourth-Line: Treatment of Hunner Lesions

• If Hunner lesions are identified on cystoscopy, fulguration and/or injection of triamcinolone should be performed to provide significant symptom relief 1, 2

Fifth-Line: Advanced Interventions for Refractory Cases

• Advanced interventions, including sacral neuromodulation, cyclosporine A, and intradetrusor botulinum toxin A, should be reserved for patients who have failed all other treatments 1, 2, 3, 4, 5
• Sacral neuromodulation has Grade C evidence with limited sample sizes and lack of durable follow-up, and is not FDA-approved for IC/BPS 3, 4, 5, 2
• Cyclosporine A and intradetrusor botulinum toxin A have Grade C evidence and are not FDA-approved for IC/BPS 3, 4, 5, 2

Pain Management Throughout Treatment

• Multimodal pain management approaches should be initiated and maintained throughout treatment, with non-opioid alternatives preferred due to the chronic nature of the condition 1, 2
• Pain management alone does not constitute sufficient treatment, and underlying bladder symptoms must also be addressed 1, 2

Treatments That Should NOT Be Offered

• Long-term oral antibiotics, intravesical BCG, intravesical resiniferatoxin, high-pressure long-duration hydrodistension, and systemic long-term glucocorticoids should not be offered due to lack of efficacy or increased risk of adverse events 2

Critical Pitfalls to Avoid

• Pelvic floor strengthening exercises should not be prescribed, and only relaxation techniques should be used 1, 2
• Baseline symptoms should be documented using validated tools, and patients should be educated on the chronic nature of IC/BPS requiring long-term management 1
• Treatment efficacy is unpredictable, and multiple therapeutic options may need to be tried before adequate symptom control is achieved 1
• Ophthalmologic examinations should be ensured for patients on pentosan polysulfate 1, 2

Pharmacologic and Pain Management Strategies for Interstitial Cystitis/Bladder Pain Syndrome

Oral Pharmacologic Therapy

• Amitriptyline, started at 10 mg daily and titrated up to 100 mg as tolerated, yields superior symptom improvement compared with placebo in patients with interstitial cystitis/bladder pain syndrome; evidence graded B. 6

Multimodal Pain Management

• Multimodal pain management alone does not constitute sufficient therapy; effective care must also target the underlying bladder symptoms in IC/BPS patients. 6
• Chronic opioid therapy should be considered only after shared decision‑making, limited to select IC/BPS patients, and accompanied by regular follow‑up to assess efficacy, adverse events, compliance, and abuse risk. 6

Treatment Expectations and Outcomes

• Adequate symptom control in IC/BPS is often achievable but typically requires trials of multiple therapeutic options, including combination regimens, because individual responses are unpredictable. 6

Guideline Summary for Interstitial Cystitis/Bladder Pain Syndrome Management

Initial Conservative Management

• Begin all patients with dietary elimination of bladder irritants (e.g., coffee, citrus, spicy foods) and pelvic‑floor relaxation exercises; if symptoms persist, progress sequentially to oral amitriptyline or pentosan polysulfate, then to intravesical agents such as heparin, lidocaine, or dimethyl‑sulfoxide, reserving cystoscopy and advanced interventions for refractory cases. 7
• All patients should start with behavioral modifications before any pharmacologic intervention is introduced. 7

Indication for Oral Pharmacotherapy

• Advance to oral medication when conservative measures are insufficient after an adequate trial, typically six weeks. 7

Cystoscopic Evaluation (Third‑Line)

• Most individuals with IC/BPS can tolerate office‑based flexible cystoscopy without performing high‑pressure, long‑duration hydrodistension. 7
• Some patients may prefer cystoscopy performed under general anesthesia for comfort. 7

Management of Hunner Lesions (Fourth‑Line)

• Hunner lesions represent the only consistent cystoscopic finding that is diagnostic for IC/BPS. 7
• Early cystoscopic diagnosis is recommended for patients in whom Hunner lesions are suspected. 7
• The majority of patients with Hunner lesions respond favorably to targeted treatment (e.g., fulguration and/or triamcinolone injection). 7